Search

Your search keyword '"Cariti G."' showing total 226 results

Search Constraints

Start Over You searched for: Author "Cariti G." Remove constraint Author: "Cariti G."
226 results on '"Cariti G."'

Search Results

2. Epidemiology, patient profile, and health care resource use for hepatitis C in Italy

5. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

6. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

11. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

13. 1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer

15. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

18. A randomized trial of pegylated-interferon-α2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

20. AISF position paper on HCV in immunocompromised patients

24. L'Italia come modello per l'Europa e per il mondo nelle politiche sanitarie per il trattamento dell'epatite cronica da HCV

26. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting

27. OPERA:use of pegylated interferon plus ribavirin for treating hepatitis C/HIV co-infrction in interferon-naive patients

28. Different HBsAg decline after 3 years of therapy with entecavir in patients affected by chronic hepatitis B HBeAg-negative and genotype A, D and E

31. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

36. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group

39. OC-34 OPERA: the use of Pegylated interferon and ribavirin for the treatment of HCV/HIV coinfection in interferon-naïve patients in Italy

41. F-33 Early ribavirin plasma concentration and ITPA polymorphisms as determinants of anemia after one month of anti-HCV therapy

42. 2002 SLC28A2 65C>T PREDICT SUSTAINED VIROLOGICAL RESPONSE IN PATIENTS WITH HEPATITIS C TREATED WITH INTERFERON AND RIBAVIRIN, CONSIDERING ALL HCV GENOTYPE AND GENOTYPE 1/4

46. Role of CYP27 B1+2838 promoter polymorphism in the treatment of chronic hepatitis B HBe Ag negative with PEG-interferon.

47. A short course of pegylated interferon‐α in acute HCV hepatitis

48. P.279 A randomised trial of pegylated interferon alpha-2a plus ribavirin with or without amantadine in the re-treatment of patients with chronic hepatitis C not responding to standard interferon and ribavirin

49. P.255 Long term follow-up of previous hepatitis C virus positive non-responders to interferon monotherapy successfully re-treated with combination therapy: are they really cured?

50. 471 Long-term follow-up of previous HCV positive non responders to interferon monotherapy successfully retreated with combination therapy (IFN-A2B + ribavirin). Results of a prospective study

Catalog

Books, media, physical & digital resources